Search results for "HIV infection"

showing 10 items of 314 documents

HIV/HCV co-infection: putting the pieces of the puzzle together

2003

The most relevant consequence of human immunodeficiency virus (HIV) infection is the exposure of the patient to opportunistic agents. In addition, HIV may also modify the natural history of some non-opportunistic pathogens, which in turn may alter the course of HIV infection.

Kupffer CellsHuman immunodeficiency virus (HIV)HIV InfectionsBiologymedicine.disease_causeTh2 CellsCytokines metabolismImmunityparasitic diseasesmedicineAnimalsHumansMolecular BiologyLiver immunologyImmunity Cellularvirus diseasesCell BiologyHepatitis Cmedicine.diseaseFibrosisHepatitis CVirologyNatural historyLiverModels AnimalImmunologyCytokinesCo infectionCell Death & Differentiation
researchProduct

Head and neck squamous cell carcinoma in people living with HIV in France.

2018

Abstract Objectives Head and neck squamous cell carcinoma (HNSCC), mainly due to smoking, is one of the leading causes of cancer deaths. However, an increasing number of tumors – especially oropharyngeal cancer – are reported in non-smokers in association with the human papillomavirus (HPV). As HIV-infected individuals are particularly at risk of HPV-related disease, we aimed to describe the burden of HNSCC in this population. Methods Retrospective chart review of patients from HIV clinics diagnosed with HNSCC between 2004 and 2014. Case patients were defined using the International Classification of Disease for Oncology (3rd edition). Age at HIV diagnosis and time from HIV diagnosis to HNS…

LarynxOncologyMalemedicine.medical_specialtyPopulationHuman immunodeficiency virus (HIV)HIV InfectionsDiseasemedicine.disease_causeCauses of cancer03 medical and health sciences0302 clinical medicineInternal medicineotorhinolaryngologic diseasesCarcinomamedicineHumans030212 general & internal medicineeducationLaryngeal NeoplasmsComputingMilieux_MISCELLANEOUSRetrospective Studieseducation.field_of_studyHypopharyngeal Neoplasmsbusiness.industrySquamous Cell Carcinoma of Head and Neckvirus diseasesCancerMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinoma[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthstomatognathic diseasesInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesis[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMouth NeoplasmsFrancebusinessMedecine et maladies infectieuses
researchProduct

Serum leptin and interleukin-6 levels in pediatric patients with HIV.

2003

Recent therapeutic approaches have improved the prognosis of children with HIV. Many new efforts could be involved in their quality of life and therefore could need additional diagnostic strategies. Leptin regulates pubertal development; furthermore a continuous immune stimulus, as in chronic infectious diseases, can enhance leptin's secretion by the action of cytokines such as interleukin (IL)-6. To clarify this role in patients infected with HIV, we assayed leptin and IL-6 and evaluated the influence of HIV severity on its secretion. IL-6 (380.5 +/- 257.6 pg/ml; range: 22-900 pg/ml) showed a significant correlation with leptinemia, HIV-1 RNA, and viremia related to the stage of HIV diseas…

LeptinMalemedicine.medical_specialtyAnti-HIV AgentsEndocrinology Diabetes and MetabolismViremiaEnzyme-Linked Immunosorbent AssayHIV InfectionsPubertal stageEndocrinologyImmune systemStatistical significanceInternal medicinemedicineHumansHIV InfectionSecretionSexual MaturationInterleukin 6ChildPediatric HIVbiologybusiness.industryInterleukin-6Reverse Transcriptase Polymerase Chain ReactionCD4 AntigenLeptinPubertyAnti-HIV AgentInterleukinInfantmedicine.diseaseEndocrinologyChild PreschoolPediatrics Perinatology and Child HealthImmunologyCD4 Antigensbiology.proteinHIV-1Receptors LeptinFemalebusinessHumanJournal of pediatric endocrinologymetabolism : JPEM
researchProduct

Expansion of the CRF19_cpx Variant in Spain

2015

Abstract Background HIV-1 CRF19_cpx, is a recombinant variant found almost exclusively in Cuba and recently associated to a faster AIDS onset. Infection with this variant leads to higher viral loads and levels of RANTES and CXCR4 co-receptor use. Objectives The goal of this study was to assess the presence of CRF19_cpx in the Spanish province of Valencia, given its high pathogenicity. Study design 1294 HIV-1 protease-reverse transcriptase (PR/RT) sequences were obtained in Valencia (Spain), between 2005 and 2014. After subtyping, the detected CRF19_cpx sequences were aligned with 201 CRF19_cpx and 66 subtype D sequences retrieved from LANL, and subjected to maximum-likelihood phylogenetic a…

Likelihood FunctionsMolecular epidemiologyPhylogenetic treeUnprotected sexBayes TheoremHIV InfectionsBiologyVirologyGroup AHIV Reverse TranscriptaseReverse transcriptaseSubtypingCoalescent theoryPhylogeographyInfectious DiseasesHIV ProteaseSpainVirologyMutationHIV-1HumansRNA ViralViral loadPhylogenyJournal of Clinical Virology
researchProduct

Adverse drug reactions to antiretroviral medication

2009

Antiretroviral therapy has greatly improved prognosis of HIV infection, with a dramatic reduction of morbidity and mortality worldwide. Nevertheless, the condition is still a common cause of death in many underdeveloped countries, where effective treatment is not always unavailable. More than 20 drugs active against HIV are commercially available, which belong to one of four groups: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion/entry inhibitors. In the near future new drugs are expected, including those of a novel group, the integrase inhibitors. To avoid viral resistance, combinations of the drugs must always b…

LipodystrophyAnti-HIV Agentsmedicine.medical_treatmentIntegrase inhibitorHIV InfectionsBioinformaticsCardiovascular SystemNervous SystemNucleoside Reverse Transcriptase InhibitorDrug HypersensitivityBone MarrowHumansMedicineEffective treatmentLactic AcidDrug reactionUrinary TractAdverse effectProteasebusiness.industryOsteonecrosisReverse transcriptaseGastrointestinal TractBone Diseases MetabolicLiverPancreatitisAntiretroviral medicationbusinessFrontiers in Bioscience
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct

Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity

2004

Abstract Objectives We sought to assess the age-specific prevalence of oral lichen planus (OLP) in Mediterranean patients with chronic hepatitis C virus (HCV) and to evaluate the features of OLP in relation to sex, smoking, HCV genotype, HIV-1 coinfection, and antiviral treatments. Methods In all, 178 anti-HCV-positive adults (60 women and 118 men; age range 20-66 years) recruited from two cohorts (104 HIV-negative patients and 74 patients with HIV coinfection) underwent oral examination. Results Overall prevalence of OLP was 2.8% (5 of 178) (male/female ratio 0.2; odds ratio=0.119; 95% confidence interval=0.013-1.106), only among HIV-negative participants, always in the reticular pattern, …

Liver CirrhosisMaleHepacivirusHIV Infectionsclinical-featureComorbidityHepacivirusmedicine.disease_causeCohort Studieschemistry.chemical_compoundPrevalenceMedicineExtrahepatic manifestationbiologySmokingvirus diseasesMiddle AgedHepatitis CCoinfectionFemalegeneral-populationmedicine.drugAdultmedicine.medical_specialtyGenotypeHepatitis C virushuman-immunodeficiency-viruDermatologyHCV hyperendemic areaAntiviral AgentsFlaviviridaeAge Distributionstomatognathic systemInternal medicineHumansInterferon alfaAgedbusiness.industryRibavirinChronic active hepatitiOdds ratiomedicine.diseasebiology.organism_classificationstomatognathic diseaseschemistrypositive patientsImmunologynegative patientliver-diseaseOral lichen planusinterferon therapybusinessLichen Planus Oral
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct